CARLAT WEBINAR Ketamine and the Evolving Psychopharmacologic Pipeline for Depression December 8, 2023 Robert C. Meisner, MD 0.50 CME Credits. Robert Meisner, MD, explores the latest developments in psychiatric treatment with ketamine and esketamine, including their differences and emerging insights for clinicians. Read More
General PsychiatryKarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change EverythingRead More
General PsychiatryPsychopharm Secrets: What Patients Won’t Tell YouHow to assess med response when the patient reports is a poor guide: long-term mood stabilizers, sleep meds, and rapid cycling.Listen now
How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered PractitionersMay 24, 2024
How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered PractitionersMay 24, 2024
How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered PractitionersMay 24, 2024
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
